Susavion Biosciences, Inc., a company focused on developing
immunotherapeutic drugs for Oncology and Infectious Diseases, announced
today it has been selected to present at the Cavendish Global Health
Impact Forum taking place May 5-7 at the United Nations Headquarters in
New York. The purpose of the Forum is to help family offices and
foundations develop and implement their individual pro-social impact
investing, grant-giving, and philanthropy programs within health and the
life sciences. To accomplish this mission, the Forum showcases
presentations and panel discussions by leading scientists, accomplished
healthcare delivery professionals, health-policy experts and
private-sector companies engaged in developing innovations with the
potential for transformational impact on disease prevention, diagnosis
and treatment. Michael Moffat, Cavendish co-founder and President
explained, "With the help of our expert advisors, we conduct a global
search of research institutions and private-sector companies in order to
identify organizations that meet the required standard of excellence.
The quality and originality of Susavion's research and scientific
insights in cancer and infectious diseases positions them to make a
major contribution to the treatment of these diseases."
"We are honored to be selected to present at this unique event, and it
is further recognition of our innovative approach to treat cancer and
infectious diseases afflicting populations around the world today," said
Dr. Laura Eggink, President of Susavion Biosciences. "We welcome the
chance to interact with many of world's leading scientific minds,
thought-leaders, and generous philanthropic individuals and amilies who
are all dedicated to the common cause of improving the health and lives
of people around the world."
Moffat explained, "Cavendish Global consists of over 150 leading
family offices and foundations from around the world with combined
assets of over $190 billion who share a passion for
pro-social endeavors within health and the life sciences." The Cavendish
Global Health Impact Forum provides family offices with a discrete,
peer-to-peer knowledge expansion and relationship building environment,
combined with the information and educational resources required by
foundations actively seeking to accelerate technological innovation and
health access through sustainable philanthropy, grant-making and impact
investing. The Forum is also an opportunity for family offices to
champion and share information on projects and organizations, which they
are passionate about with other family offices from around the world.
Cavendish Global together with the Global Partnerships Forum and the New
York Academy of Sciences organizes the Forum annually in New York.
About Susavion Biosciences, Inc.
The founders of Susavion Biosciences, Dr. Laura L. Eggink and Dr. J.
Kenneth Hoober, developed a platform of novel peptide drugs, which have
the potential to provide a breakthrough approach for treating diseases
around the world. Susavion is well-positioned to capitalize on the
emerging opportunities in immunotherapeutics for todays's most
Further information is available on the Company's website, www.susavion.com.
About Cavendish Global (http://cavendishglobal.com)
Cavendish Global provides family offices and their foundations with a
discrete, peer-to-peer knowledge expansion and relationship building
environment, combined with the innovative resources required to help
develop and implement their individual pro-social impact investment,
grant making and philanthropy programs within health and the life
sciences. Cavendish Global provides family offices with a number of
innovative resources, which includes Cavendish Impact Forums. A unique
gathering of leading family offices, Cavendish Impact Forums take place
three times each year; in the United States (NYC, May 2014),
Europe (London, October 2014) and a third event held at a Cavendish Host
Partner City which moves to a different global location each
year (Dubai, UAE January 2015).
For more information: http://cavendishglobal.com
[ Back To NFVZone's Homepage ]